Verve Therapeutics Inc.
13F holders, Q4 2025 (December 31)3holders
0new positions
0sold out
$0.00avg. 13F price*
At the end of Q4 2025, 3 institutions reported holding Verve Therapeutics Inc. in their 13F filings, unchanged from Q3 2025. 0 opened new positions and 0 sold out. The largest holders were Cim Investment Management Inc. ($0), GAMMA Investing LLC ($0) and Murphy & Mullick Capital Management Corp ($0).
- Company
- Verve Therapeutics Inc.
- Filed as
- Contra Verve Therapeutic (Q4 2025)
- CUSIP
- 925CVR011
- Latest filing quarter
- Q2 2026
History
Number of 13F holders
Total Exit/New Position Q3 2025 → Q4 2025
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 0 | $0 |
Ownership 3 holders
| Cim Investment Management Inc. | 0.00% | No change | 25,747 | $0 |
| GAMMA Investing LLC | 0.00% | No change | 257 | $0 |
| Murphy & Mullick Capital Management Corp | 0.00% | No change | 43 | $0 |
"% of holder's portfolio" is VERVE THERAPEUTICS INC's weight in each manager's 13F, not the share of Verve Therapeutics Inc. the manager owns.